天坛生物：“皮下注射人免疫球蛋白”、“注射用重组人凝血因子Ⅶa”两个新产品已完成临床试验

Group 1 - The company has not launched any new products so far this year [2] - Two new products, "subcutaneous injection of human immunoglobulin" and "recombinant human coagulation factor VIIa for injection," have completed clinical trials and submitted for market approval [2]